Saturday, September 3, 2011

Blog Reprint from the "MAD SCIENTIST" (aka) "PHARYNGULA"

******
******
Dichloroacetate (DCA) and Cancer

Category: Science
Posted on: May 16, 2011 10:02 AM, by PZ Myers (PZ Myers is a biologist and associate professor at the University of Minnesota, Morris.)


So many people have sent me this sensationalistic article, "Scientists cure cancer, but no one takes notice", that I guess I have to respond. I sure wish it were true, but you should be able to tell from how poorly it is written and the ridiculous inaccuracies (mitochondria are cells that fight cancers?) that you should be suspicious. The radical, exaggerated claims make the truth of the story highly unlikely.

Researchers at the University of Alberta, in Edmonton, Canada have cured cancer last week, yet there is a little ripple in the news or in TV. It is a simple technique using very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders. So, there is no concern of side effects or about their long term effects.

The simple summary is this: that claim is a lie. There have been no clinical trials of dichloroacetate (DCA) in cancer patients, so there is no basis for claiming they have a cure; some, but not all, cancers might respond in promising ways to the drug, while others are likely to be resistant (cancer is not one disease!); and there are potential neurotoxic side effects, especially when used in conjunction with other chemotherapies.

So we have one popular account that is badly written and makes exaggerated claims. There is also a university press release, the source for the sloppy popular account, that doesn't contain the egregious stupidities but does tend to inflate basic research studies into an unwarranted clinical significance. And then, of course, there are the actual peer reviewed papers that describe the research and rationale, and also the reservations, on DCA. It's like a game of telephone: you can actually trace the account from the sober science paper to the enthusiastic press release to the web account with its extravagant claims of a simple, cheap cure for cancer, and see how the story is gradually corrupted. It would be funny if the final result wasn't going to dupe a lot of desperate people.

But there is a germ of truth to the story, in that DCA does have potential. Here's how it works.

There are two major pathways that we use to extract energy from sugar. One is glycolysis, which extracts two ATP molecules from each molecule of sugar, and doesn't require oxygen. Then there is glucose oxidation, which as you might guess from the name, does require oxygen, but which takes the byproducts of glycolysis and burns them completely to produce 36 ATP. So there's the tradeoff: if your cells are oxygen-starved, or hypoxic, they can still get energy from sugar, but it's relatively inefficient, but if they do have access to oxygen, they can extract much more. This is why you breathe, and why your heart beats, and why you have an elaborate circulatory system to deliver oxygenated blood to your tissues: without oxygen, you suffer a catastrophic hit to the efficiency of energy production.


Another feature of these two energy-producing pathways is that they are in different cellular compartments. Glycolysis takes place in the cytoplasm, while glucose oxidation occurs in the mitochondria. There is a gate-keeping enzyme, pyruvate dehydrogenase kinase (PDK), that regulates the flow of pyruvate, a product of the glycolysis pathway, into the mitochondria for oxidation. If PDK is active, it suppresses the transport of pyruvate into the mitochondria, and the cell is forced to rely on glycolysis, even if oxygen is available. If PDK is inactivated, pyruvate is shuttled into the mitochondria, even if oxygen is low.

This is where DCA comes in. DCA inhibits PDK, forcing cells to use the more efficient form of energy production. That sounds like a strange way to make a cancer cell uncomfortable, but the other factor here is that mitochondria are primary regulators of apoptosis, or cell suicide. They are loaded with sensors and enzymes that react to abnormalities in the cell (like being cancerous!) by activating a self-destruct mechanism. Shut down the mitochondra, you shut down the self-destruct mechanism that polices the cell. So the idea is a little indirect: by goosing the mitochondria, we also wake up the safety switch that, if all goes well, will cause the cell to spontaneously kill itself.

There are good reasons to think this might work. Many cancer cells arise in hypoxic environments; a poorly vascularized tumor, for instance, is going to be oxygen starved in the absence of blood flow, and the inhibition of mitochondria may be a factor in their survival. There is a well-known phenomenon called the Warburg effect, in which cancer cells will rely on glycolysis even when oxygen is available, suggesting that they have suppressed their mitochondria.

DCA also seems like a relatively safe drug. It's been used for a long time in patients with metabolic disorders, or with metabolic side effects from other problems.

A large number of children and adults have been exposed to DCA over the past 40 years, including healthy volunteers and subjects with diverse disease states. Since its first description in 1969, DCA has been studied to alleviate the symptoms or the haemodynamic consequences of the lactic acidosis complicating severe malaria, sepsis, congestive heart failure, burns, cirrhosis, liver transplantation and congenital mitochondrial diseases. Single-arm and randomised trials of DCA used doses ranging from 12.5 to 100 mg kg-1 day-1 orally or intravenously). Although DCA was universally effective in lowering lactate levels, it did not alter the course of the primary disease (for example sepsis).

This is encouraging. It means there is a body of work already published on the effects of DCA, which should simplify the process of moving it into clinical trials. The authors, however, very clearly indicate that it won't be a magic bullet affecting all cancers, but that some are likely candidates.

Dichloroacetate could be tested in a variety of cancer types. The realisation that (i) a diverse group of signalling pathways and oncogenes result in resistance to apoptosis and a glycolytic phenotype, (ii) the majority of carcinomas have hyperpolarised/ remodeled mitochondria, and (iii) most solid tumours have increased glucose uptake on PET imaging, suggest that DCA might be effective in a large number of diverse tumours. However, direct preclinical evidence of anticancer effects of DCA has been published only with non-small cell lung cancer, glioblastoma and breast, endometrial and prostate cancer. In addition, the lack of mitochondrial hyperpolarisation in certain types of cancer, including oat cell lung cancer, lymphomas, neuroblastomas and sarcomas, suggest that DCA might not be effective in such cases. Cancers with limited or no meaningful therapeutic options like recurrent glioblastoma or advanced lung cancer should be on top of the list of cancers to be studied.

Notice that the only work done so far is preclinical: that means it has been tested in mouse models, tissue culture, but hasn't really been tried in cancer patients yet. The authors come right out and say that, express some possible reservations about its effectiveness, and suggest what needs to be done next.

No patient with cancer has received DCA within a clinical trial. It is unknown whether previously studied dose ranges will achieve cytotoxic intra-tumoral concentrations of DCA. In addition, the overall nutritional and metabolic profile of patients with advanced cancer differs from those in the published DCA studies. Furthermore, pre-exposure to neurotoxic chemotherapy may predispose to DCA neurotoxicity. Carefully performed phase I dose escalation and phase II trials with serial tissue biopsies are required to define the maximally tolerated, and biologically active dose. Clinical trials with DCA will need to carefully monitor neurotoxicity and establish clear dose-reduction strategies to manage toxicities. Furthermore, the pharmacokinetics in the cancer population will need to be defined.

Do not rush out and buy DCA and gurgle it down as a cancer preventative. We don't know that it works — the safe concentrations for you may not be sufficient to kill any cancer cells, and the concentrations needed to kill cancer cells may be so high that it will do horrible, unpredicted, and dangerous things to you (some work with patients with congenital mitochondrial disorders also revealed some degree of peripheral neuropathy, for instance). This is why we have clinical trials: to work out safe and effective doses, look for dangerous interactions with other drugs — and if you have cancer, you're already on a complicated cocktail of drugs — and detect unexpected side effects.

We should be urging further investigation of this promising drug with the beginning of clinical trials, but it's far too early to be babbling about "cancer cures". There have been lots of drugs that look great in the lab and have excellent rationales for why they should work, but the reality of cancer is that it is complicated and diverse and there are many more pitfalls between a drug that poisons cancer cells in a petri dish and a drug that actually works well in the more complex environment of a human being.

One other factor that inflames the conspiracy nuts over this drug is that DCA is simple, dirt-cheap, and completely unpatentable — there is no economic incentive for a pharmaceutical company to invest a gigantic bucket of money in clinical trials, because there is no hope for a return on the investment.

This is why an independent academic community with research funded for knowledge rather than profit is so important, and really emphasizes why we cannot afford to privatize all biomedical research. The authors propose a plan for progressing without the involvement of the pharmaceutical industry.

Funding for such trials would be a challenge for the academic community as DCA is a generic drug and early industry support might be limited. Fundraising from philanthropies might be possible to support early phase I - II or small phase III trials. However, if these trials suggest a favourable efficacy and toxicity, the public will be further motivated to directly fund these efforts and national cancer organisations like the NCI, might be inspired to directly contribute to the design and structure of larger trials. It is important to note that even if DCA does not prove to be the 'dawn of a new era', initiation and completion of clinical trials with a generic compound will be a task of tremendous symbolic and practical significance. At this point the 'dogma' that trials of systemic anticancer therapy cannot happen without industry support, suppresses the potential of many promising drugs that might not be financially attractive for pharmaceutical manufacturers. In that sense, the clinical evaluation of DCA, in addition to its scientific rationale, will be by itself another paradigm shift.

I can't blame the industry for not following up on this: a clinical trial costs millions of dollars, and even if DCA pans out, there is no profit at all to be gained from it. For this research, we have to turn to public support (they have an interest in better cancer treatments!) and to scientists and doctors themselves, who of course have a great personal interest in seeing their patients get better.




Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99(7):989-94.


Thursday, August 25, 2011

Jilted ??

******
******
I feel like a jilted school girl, waiting by the phone to hear from the jerk that couldn't even remember my name the next morning...hoping that he will call asking for that second date (not that I would ever know what that was like).

The surgical onc and radiation onc - who work in tandem, were both adamant about the urgency of me getting the breast MRI. Which was done a day and half after I saw radiation onc, and scheduled by her office while I was there. Radiation onc was "not comfortable" with me waiting to have the recommended surgery after I got back from moving my 19 year old into her sophomore dorms. I would be flying back from New Hampshire on September 12. When I left surgical one's office she said that soon as she got the MRI results we would needed to do a sit down and schedule surgery - she said she would call.

"Nurse Ratched" at radiation onc's office told Mary (see last post) that radiation onc was going to call me imminently.

Urgency, urgency, urgency. Hurry up and wait.

It has now been 8 days since I saw surgical onc. Seven days since I saw radiation onc. Six days since I had the MRI. Four days since the report arrived on their respective fax machines.



I have not had a ring from anyone. Jilted!       

But, like every self-respecting school-girl, I am like soooo over them! [Insert: rolling of eyes, and a toss of the hair with hip jutted out for emphasis.]      

As with all, smart, jilted lovers (and yes, that was a self-serving pat on the back!) I have moved on to alternative pastures. Dr. John, ND (who is much cuter than either of the aforementioned ladies, btw) gave me my first Ozone Therapy treatment last evening. Besides a bruised vein and sore bicep, not too bad. Saturday I have the first of four sessions in the Life Vessel (Google it. Its right up there with the pods from Invasion of the Body Snatchers!), and I am topping off my Saturday with an IV nightcap of high dose vitamin C. Check out older posts from 2010 - four installments on therapeutic benefits of vitamin C. (Not that it seemed to be 100% effective during ILC-Round #1.)


Tuesday, August 23, 2011

John C. Lincoln Breast Health & Research Center...Revisited

******
******
Sigh...they call, but they don't leave voice mail messages. Not even a cursory message identifying themselves and asking for a call back. Why is that?

Hi. This is TC...I missed a call from you?

That wasn't me, I will forward you to our scheduler.

No, I don't need to schedule. I am trying to find out whether my Breast MRI results are completed.

That would be Mary. One moment.

This is Mary...Yes, they are ready. I am faxing them over to Radiation Onc right now.

Can you fax them to me as well.  
The 5 ft Pink Ribbon
announcing that you
have arrived at BH&RC
 No. HIPAA does not allow me. Call Radiation Onc and she can tell you the results. 

Right. Can you tell me the results.

No. HIPAA does not allow me to do that. I am not a nurse or doctor. Call Radiation Onc.

You see Mary, Radiation Onc and her personal "Nurse Ratched" are not good doing "phone."

If you were here, I could hand you the report.

I will come, and call Radiation Onc.

I leave a voice mail message for Radiation Onc as well as"Nurse Ratched."

I arrive at BH&RC. I wait for Mary. While I am waiting, I snap a few pics of the main reception area with my cell phone - being careful not to violate any one's privacy. The pic of the glowing pink pony wall doesn't give it illuminating justice.
One of 3 Glowing Pink
Pony Walls in the
 Reception Area

Mary comes out and meets with me. Apologizes for the restraint that she is under. Mary asks me if I have spoken with Radiation Onc, because she confirmed with "Nurse Ratched" that they received the report; and she let them know I was asking for my results. "Nurse Ratched" reportedly assured Mary that they would call me first thing.

No. They didn't.

Mary gives me the report - YEAH...Good news, kinda: "...[no] suspicious areas of enhancement on the right side. Oval mass [in left axillary tail] is consistent with a pathological lymph node and is positive for malignancy." Okay, nothing new, thank you Mary. But...Mary, the report states: "No prior exams were available for comparison. What happened to the three CDs I left with the nurse for the sole purpose of comparison?"

Cell Phone does not quite capture the
sparkly nature of the Reception chandelier
You left us films?               

Yes. Three CDs: first Breast MRI; PetScan; and Breast Ultrasounds.




View to the left of the door
leading into the MRI exam




Excuse me. Let me locate those. . Yes, we have located those and the report will have to be amended after Doctor reviews. My apologies for the inconvenience.

Mary is nice. Never shoot the messenger.






BTW - its is 6:30 p.m. PST. Radiation Onc's office has not called.

Pinktoberfest Already...Its Only August...Yuk!

******
******
Now this is a a guitar I would like see shredded on stage!




Hard Rock Pinktober Guitar 2011 -- Pinktober is going the way of the bermuda triangle of holdiays (Thanksgiving, Christmas & New Year)...starting earlier and earlier so retailers can get a jump start on their profit margin. Yipee skipee!

Sunday, August 21, 2011

Getting a Handle on the Abbreviations & Acronyms

******
******
My Own Little "AA" Pocket Reference

ALND = axillary lymph node dissection
ANS = Autonomic Nervous System (ANS)
BILAT = bilateral
BHRT = bioidentical hormonal replacement therapy
BRCA = breast cancer type 1 susceptibility protein
CAM = complimentary alternative medicine
CNS = central nervous system
CT = computerized tomography
DCA = dichloroacetate
DCIS = ductal carcinoma in-situ
DFS = disease-free survival
EGFR = epidermal growth factor receptor
ER = estrogen receptor
IDC = infiltrating (invasive) ductal carcinoma
ILC = infiltrating (invasive) lobular carcinoma
LCIS = lobular carcinoma in-situ
METS - metastatic
MRI =  magnetic resonance imaging
OS = overall survival
PetScan [PET] = positron emission tomography
PgR = progesterone receptor
SNLB = sentinel node biopsy

I will be adding to this list as I learn more during this next stage. This is just the basic primer for now.